Summary
Regeneron Pharmaceuticals, Inc. reported its financial results for the nine months and third quarter ended September 30, 2004. The company significantly increased its total revenue to $127.0 million for the nine-month period, up from $36.2 million in the prior year, largely driven by collaborations with Aventis for VEGF Trap and Novartis for IL-1 Trap. Despite a substantial increase in revenue, the company remains in a net loss position for the nine months, reporting $38.9 million in net income, a significant improvement from a $88.1 million net loss in the same period of 2003. This turnaround is partly due to a $42.75 million payment received from Novartis as they withdrew from the IL-1 Trap collaboration, and a $17.8 million loan forgiveness by Novartis upon achievement of a development milestone. Financially, Regeneron ended the period with $105.0 million in cash and cash equivalents and $168.1 million in marketable securities. While the company has seen revenue growth, it continues to invest heavily in research and development, with R&D expenses remaining significant. The company anticipates continued substantial funding requirements for research and development activities and believes its existing capital resources will support operations through at least the end of 2006.
Key Highlights
- 1Total revenue for the nine months ended September 30, 2004, surged to $127.0 million, a significant increase from $36.2 million in the same period of 2003, primarily due to collaboration revenues from Aventis (VEGF Trap) and Novartis (IL-1 Trap).
- 2The company reported a net income of $38.9 million for the nine months ended September 30, 2004, a notable improvement from a net loss of $88.1 million in the corresponding period of 2003.
- 3A key driver of improved profitability was a $42.75 million payment from Novartis in Q1 2004 following their decision to withdraw from the IL-1 Trap collaboration, and the forgiveness of $17.8 million in loans from Novartis.
- 4Cash and cash equivalents decreased to $105.0 million as of September 30, 2004, from $118.3 million at the end of 2003, reflecting substantial investment in marketable securities and ongoing R&D expenses.
- 5Research and development expenses for the nine months remained substantial at $101.3 million, only a slight decrease from $102.8 million in the prior year, indicating continued significant investment in pipeline development.
- 6The VEGF Trap is advancing, with Aventis collaborating on oncology and ophthalmology indications, including new trials planned for 2005 and additional studies for eye diseases.
- 7Regeneron's leadership believes its current capital resources are sufficient to fund operations through at least the end of 2006, but acknowledges the need for potential future financing.